New Delhi, July 07, 2015: Biotechnology firm Transgene BiotekBSE 4.67 % has received patent in the US for its novel molecule to be developed for treatment of liver cancer.
“This granting of a USA patent is a significant step in moving ahead with the development of this novel drug,” Transgene Biotek said in a filing to the BSE.
The company’s novel molecule miRNA 101 for therapy against liver cancer has been allowed for issuance of a USA patent after the prosecution on merits have been closed, it added.
Hepato-cellular cancer (HCC) is the most common primary liver cancer, accounting to roughly 90 per cent of this class of malignancy, with poor prognosis due to its ability to rapidly spread, Transgene Biotek said.
The company’s current product portfolio covers segments such as oncology, auto-immunity, drug delivery and bio-generics.
Shares of Transgene Biotek closed 4.90 per cent up at Rs 2.57 per scrip on the BSE. PTI
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…